Literature DB >> 10821536

Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells.

G Portella1, D Vitagliano, C Borselli, R M Melillo, D Salvatore, J L Rothstein, G Vecchio, A Fusco, M Santoro.   

Abstract

The ras family members and the tyrosine kinases RET and TRK are frequently activated in human tumors of the thyroid gland. To ascertain the effects of these oncogenes in cultured thyroid cells we have generated expression vectors containing activated versions of the three genes under the control of the thyroid-specific thyroglobulin gene promoter. Here we show that the expression of the three oncogenes differently affects thyroid differentiation. While the TRK-T1 oncogene interferes with the capability of thyroid cells of trapping iodide and only marginally affects thyroglobulin gene expression, both RET/PTC3 and N-ras(Gln61-Lys) induce a dramatic reduction of thyroglobulin mRNA and alleviate TSH dependency for cellular growth. However, none of the three oncogenes is able to induce the appearance of neoplastic transformation markers, such as growth in semisolid medium and tumorigenicity in athymic mice. This indicates that genetic events additional to TRK, RET, or N-ras activation are required for fully malignant transformation of thyroid cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10821536

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  9 in total

1.  Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Authors:  Debyani Chakravarty; Elmer Santos; Mabel Ryder; Jeffrey A Knauf; Xiao-Hui Liao; Brian L West; Gideon Bollag; Richard Kolesnick; Tin Htwe Thin; Neal Rosen; Pat Zanzonico; Steven M Larson; Samuel Refetoff; Ronald Ghossein; James A Fagin
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

2.  Thyroid cancer: pathogenesis and targeted therapy.

Authors:  David A Liebner; Manisha H Shah
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 3.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

Review 4.  Thyroid cancer stem cells.

Authors:  Reigh-Yi Lin
Journal:  Nat Rev Endocrinol       Date:  2011-07-26       Impact factor: 43.330

5.  Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer.

Authors:  Júlio Cezar Marques Ricarte-Filho; Cesar Seigi Fuziwara; Alex Shimura Yamashita; Eloiza Rezende; Marley Januário da-Silva; Edna Teruko Kimura
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

6.  Resistance of papillary thyroid cancer stem cells to chemotherapy.

Authors:  Raffaella Giuffrida; Luana Adamo; Gioacchin Iannolo; Luisa Vicari; Dario Giuffrida; Adriana Eramo; Massimo Gulisano; Lorenzo Memeo; Concetta Conticello
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

7.  Autophagy: A potential target for thyroid cancer therapy (Review).

Authors:  Heqing Yi; Bin Long; Xuemei Ye; Lijun Zhang; Xiaodong Liu; Chunyan Zhang
Journal:  Mol Clin Oncol       Date:  2014-06-06

8.  Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.

Authors:  Hong Dong; Wen-Zhuang Shen; Yu-Jing Yan; Ji-Lin Yi; Lin Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-02-03

Review 9.  The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.

Authors:  Aniello Cerrato; Roberta Visconti; Angela Celetti
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.